Dupilumab as a Treatment for Allergic Contact Dermatitis

Chipalkatti, Naina; Lee, Nicole; Zancanaro, Pedro; Dumont, Nicole; Donovan, Courtney; Rosmarin, David

doi:10.1097/der.0000000000000414

Cited by 32 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Silvestre et al [76] Case reports and small case series have shown that patients with refractory allergic contact dermatitis to specific allergens, for which contact avoidance was not possible, improved after starting dupilumab. With or without AD, the patients responded similarly with improvement in itching and skin lesions after 2 weeks to 6 months [102][103][104][105][106][107]. In contrast, 1 patient developed recall dermatitis at a colophony patch test site on starting treatment with dupilumab, suggesting that dupilumab may unbalance the T H 1/T H 2 response to certain contactants [108].…”

Section: Prurigo Nodularismentioning

confidence: 96%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

Recent advances in understanding T2 inflammation have broadened the diseases in which T2 inflammation can be involved. Dupilumab is a recently developed monoclonal antibody blocking the signaling of both IL-4 and IL13, two crucial cytokines of the T2 responses. New possible indications are increasingly exploring. Among them are skin diseases, such as prurigo nodularis, nummular eczema, allergic contact dermatitis, chronic hand eczema, spontaneous chronic urticaria, bullous pemphigoid, alopecia areata, and Netherton syndrome, among other several cutaneous diseases. Also, respiratory diseases, such as allergic bronchopulmonary aspergillosis, chronic eosinophilic pneumonia, and allergic rhinitis. In addition, eosinophilic gastrointestinal disorders, particularly eosinophilic esophagitis, and food allergy are two more research fields. Here we review the published data and clinical trials about the use of dupilumab in these disorders.

show abstract

Section: Prurigo Nodularismentioning

confidence: 96%

Dupilumab: A Review of Present Indications and Off-Label Uses

Muñoz-Bellido¹,

Moreno²,

Dávila³

2022

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…In all cases, the dermatitis improved while the patients were receiving dupilumab. Chipalkatti and Lee reported two patients with ACD who improved significantly while receiving dupilumab . Patch tests showed positive reactions to multiple allergens (mainly biocides and fragrances).…”

Section: Discussionmentioning

confidence: 99%

Blocking type 2 inflammation by dupilumab does not control classic (type 1‐driven) allergic contact dermatitis in chronic hand eczema

2019

View full text Add to dashboard Cite

“…16 Dupilumab treatment has also been reported to have a significant therapeutic effect on allergic contact dermatitis. 24,25 The possibility of rosacea-like reaction explaining dupilumab facial dermatitis is supported by clinical features of episodic flushing and telangiectasia and histologic features of some dilated blood vessels and perifollicular infiltrates. 8,21,26 A clinical improvement by minocycline additionally supports the theory as reported in one case.…”

Section: Discussionmentioning

confidence: 99%

Facial erythema in patients with atopic dermatitis treated with Dupilumab – a descriptive study of morphology and Aetiology

Ahn

Lee

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background The development of dermatitis on face and neck, which was not described in phase 3 clinical trials, has been reported in the literature in patients treated with dupilumab. Little is known regarding the causes or defining features of the facial dermatitis. Objectives We conducted surveys of consecutive patients with AD on dupilumab to describe its clinical features, morphology and aetiology. Methods A multi‐centre prospective cohort study was conducted from 1 January 2020, to 31 December 31 2020. A total of 162 patients under dupilumab treatment were asked to complete a questionnaire and patients were evaluated by dermatologists. Results Of all 162 patients, 137 (84.6%) patients reported pre‐existing facial dermatitis prior to dupilumab therapy. One hundred and twenty‐one (88.3%) patients with pre‐existing facial dermatitis reported improvement of their facial dermatitis with dupilumab therapy, nine (6.6%) patients reported no change after the treatment and seven (4.3%) patients of them got worse after the treatment (exacerbation group). Of 25 patients who reported no pre‐existing active facial dermatitis, six (24%) patients reported new‐onset facial erythema after the starting dupilumab therapy (new‐onset group). A large proportion of the patients in both the exacerbation (86%) and new‐onset groups (67%) had a history of facial TCS use. Both groups showed similar clinical manifestations and distribution with few differences. Conclusions The vast majority of patients treated with dupilumab in academic institutions from Korea and the United States experienced improvement in their facial dermatitis with dupilumab therapy. A small proportion of patients had new onset and exacerbation. Although the mechanisms of this adverse event remain unclear, steroid withdrawal should be considered as a diagnosis of the erythema in some patients.

show abstract

Dupilumab as a Treatment for Allergic Contact Dermatitis

Cited by 32 publications

References 3 publications

Dupilumab: A Review of Present Indications and Off-Label Uses

Dupilumab: A Review of Present Indications and Off-Label Uses

Blocking type 2 inflammation by dupilumab does not control classic (type 1‐driven) allergic contact dermatitis in chronic hand eczema

Facial erythema in patients with atopic dermatitis treated with Dupilumab – a descriptive study of morphology and Aetiology

Contact Info

Product

Resources

About